Lyra Therapeutics (LYRA)
(Real Time Quote from BATS)
$0.25 USD
-0.01 (-3.48%)
Updated Oct 2, 2024 09:56 AM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
LYRA 0.25 -0.01(-3.48%)
Will LYRA be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for LYRA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LYRA
Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Tops Revenue Estimates
Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates
LYRA: What are Zacks experts saying now?
Zacks Private Portfolio Services
OptiNose (OPTN) Reports Q2 Loss, Lags Revenue Estimates
Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Tops Revenue Estimates
Lyra Therapeutics (LYRA) Soars 6.5%: Is Further Upside Left in the Stock?
Other News for LYRA
Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings
Lyra Therapeutics still sees potential in rhinosinusitis asset despite setbacks
Lyra Therapeutics (LYRA) Receives a Hold from BTIG
Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
LYRA Stock Earnings: Lyra Therapeutics Beats EPS, Beats Revenue for Q2 2024